Success Metrics

Clinical Success Rate
53.3%

Based on 8 completed trials

Completion Rate
53%(8/15)
Active Trials
1(3%)
Results Posted
150%(12 trials)
Terminated
7(23%)

Phase Distribution

Ph phase_2
7
23%
Ph phase_1
24
77%

Phase Distribution

24

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution31 total trials
Phase 1Safety & dosage
24(77.4%)
Phase 2Efficacy & side effects
7(22.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

26.7%

8 of 30 finished

Non-Completion Rate

73.3%

22 ended early

Currently Active

1

trials recruiting

Total Trials

31

all time

Status Distribution
Active(1)
Completed(8)
Terminated(22)

Detailed Status

Withdrawn15
Completed8
Terminated7
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
1
Success Rate
53.3%
Most Advanced
Phase 2

Trials by Phase

Phase 124 (77.4%)
Phase 27 (22.6%)

Trials by Status

completed826%
withdrawn1548%
terminated723%
active_not_recruiting13%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT02523469Phase 1

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Completed
NCT02782546Phase 2

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Active Not Recruiting
NCT03381586Phase 1

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

Completed
NCT03169790Phase 1

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Withdrawn
NCT03169764Phase 1

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03647423Phase 1

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Withdrawn
NCT03167164Phase 1

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn
NCT03574649Phase 2

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn
NCT03167177Phase 1

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03563144Phase 2

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn
NCT03554109Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn
NCT03197571Phase 1

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03169738Phase 1

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn
NCT03169777Phase 1

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn
NCT03197584Phase 1

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Withdrawn
NCT03175666Phase 1

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn
NCT01946789Phase 1

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Completed
NCT03329248Phase 1

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated
NCT03563157Phase 1

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated
NCT03586869Phase 1

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
31